Summary by Futu AI
Anthony P. Adamis, associated with EyePoint Pharmaceuticals, Inc. [EYPT], completed a transaction on June 23, 2024, acquiring 2,000 shares of common stock at no cost. This transaction was categorized as an exercise or conversion of derivative security, conducted directly by Adamis. Following this acquisition, Adamis's direct holdings in EyePoint Pharmaceuticals increased to a total of 4,000 shares of common stock.